Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12646137 | 0.82 | MAPK1 (0.58) | MAPK1CYP1A2CYP2C19LMNAHTT | |
| SCHEMBL2175235 | 0.82 | MAPK1 (0.68) | MAPK1CYP1A2CYP2C19LMNAHTT | |
| SCHEMBL2827052 | 0.80 | KDM4E (0.57) | MAPK1CYP1A2CYP2C19LMNAHTT | |
| SCHEMBL27726904 | 0.78 | MAPK1 (0.52) | MAPK1CYP1A2CYP2C19LMNAHTT | |
| SCHEMBL13240613 | 0.77 | MAPK1 (0.51) | MAPK1CYP1A2CYP2C19LMNAHTT | |
| SCHEMBL2823777 | 0.77 | MAPK1 (0.51) | MAPK1CYP2C19HTTALDH1A1KDM4E | |
| SCHEMBL14108789 | 0.76 | MAPK1 (0.39) | MAPK1LMNAHTTALDH1A1KDM4E | |
| SCHEMBL19253553 | 0.75 | ALDH1A1 (0.41) | CYP1A2LMNAALDH1A1KDM4ENPC1 | |
| SCHEMBL14547115 | 0.74 | MAPK1 (0.49) | MAPK1CYP1A2CYP2C19LMNAHTT | |
| SCHEMBL28469060 | 0.74 | LMNA (0.36) | MAPK1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020200154-A1 | A CLASS OF THIOPHENE FUSED N-HETEROCYCLIES, PREPARATION METHOD AND USE | 上海凌达生物医药有限公司 | 2020-10-08 | — | — | WO | disclosed |
| US-20140364415-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2014-12-11 | — | — | US | disclosed |
| US-8846698-B2 | Pyrrolo[2,3-d]pyrimidine tropomysin-related kinase inhibitors | PFIZER LIMITED (US) | 2014-09-30 | — | — | US | disclosed |
| US-20120258950-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2012-10-11 | — | — | US | disclosed |
| US-20100173888-A1 | Nicotinamide Derivatives | PFIZER INC | 2010-07-08 | — | — | US | disclosed |
| WO-2009153720-A1 | NICOTINAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364415-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | DMPK, DTYMK, MUSK | MAPK1 241/4885CYP1A2 3220/4885CYP2C19 2821/4885 |
| US-20100173888-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | MAPK1 1907/4885CYP1A2 397/4885CYP2C19 302/4885 |
| US-20120258950-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | DMPK, DTYMK, MUSK | MAPK1 241/4885CYP1A2 3220/4885CYP2C19 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.